Copyright: Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd.! 京ICP备19006400号-1 Powered by 300.cn
美科
Links:
Stemedica Cell Technologies, Inc., a US company with investment from JZT, received US FDA emergency IND approval for using its bone marrow-derived mesenchymal stem cells to treat severe COVID-19 cases.
Source:
Release time:
2020/04/20 14:06
Page view
Stemedica Cell Technologies, Inc., a US company with investment from JZT, received US FDA emergency IND approval for using its bone marrow-derived mesenchymal stem cells to treat severe COVID-19 cases.